This database contains 201 studies, archived under the term: "double-blind method"
Click here to filter this large number of results.
Donepezil and memantine for moderate-to-severe Alzheimer’s disease
Howard, Robert,
McShane, Rupert,
Lindesay, James,
Ritchie, Craig,
Baldwin, Ashley,
Barber, Robert,
Burns, Alistair,
Dening, Tom,
Findlay, David,
Holmes, Clive,
Hughes, Alan,
Jacoby, Robin,
Jones, Rob,
Jones, Roy,
McKeith, Ian,
Macharouthu, Ajay,
O'Brien, John,
Passmore, Peter,
Sheehan, Bart,
Juszczak, Edmund,
Katona, Cornelius,
Hills, Robert,
Knapp, Martin,
Ballard, Clive,
Brown, Richard,
Banerjee, Sube,
Onions, Caroline,
Griffin, Mary,
Adams, Jessica,
Gray, Richard,
Johnson, Tony,
Bentham, Peter,
Phillips, Patrick
Background: Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.; Methods: We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s […]
Memantine for dementia in adults older than 40 years with Down’s syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Hanney, Marisa,
Prasher, Vee,
Williams, Nicola,
Jones, Emma L.,
Aarsland, Dag,
Corbett, Anne,
Lawrence, Dale,
Yu, Ly-Mee,
Tyrer, Stephen,
Francis, Paul T.,
Johnson, Tony,
Bullock, Roger,
Ballard, Clive
Background: Prevalence of Alzheimer’s disease in people with Down’s syndrome is very high, and many such individuals who are older than 40 years have pathological changes characteristic of Alzheimer’s disease. Evidence to support treatment with Alzheimer’s drugs is inadequate, although memantine is beneficial in transgenic mice. We aimed to assess safety and efficacy of memantine […]
Memantine and brain atrophy in Alzheimer’s disease: a 1-year randomized controlled trial
Wilkinson, David,
Fox, Nick C.,
Barkhof, Frederik,
Phul, Ravinder,
Lemming, Ole,
Scheltens, Philip
The primary objective of this study was to evaluate the rate of total brain atrophy (TBA) with serial magnetic resonance imaging (MRI), using the Brain Boundary Shift Integral (BBSI), in patients with probable Alzheimer’s disease (AD) over the course of 52 weeks of treatment with memantine or placebo. This was a multi-national, randomized, double-blind, placebo-controlled, […]
Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study
Winblad, Bengt,
Andreasen, Niels,
Minthon, Lennart,
Floesser, Annette,
Imbert, Georges,
Dumortier, Thomas,
Maguire, R. Paul,
Blennow, Kaj,
Lundmark, Joens,
Staufenbiel, Matthias,
Orgogozo, Jean-Marc,
Graf, Ana
Background: Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer’s disease. We aimed to assess the safety and tolerability of CAD106, a novel active Aβ immunotherapy for patients with Alzheimer’s disease, designed to induce N-terminal Aβ-specific antibodies without an Aβ-specific T-cell response.; Methods: We did a phase […]
Study of the use of antidepressants for depression in dementia: the HTA-SADD trial–a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine
Banerjee, S.,
Hellier, J.,
Romeo, R.,
Dewey, M.,
Knapp, M.,
Ballard, C.,
Baldwin, R.,
Bentham, P.,
Fox, C.,
Holmes, C.,
Katona, C.,
Lawton, C.,
Lindesay, J.,
Livingston, G.,
McCrae, N.,
Moniz-Cook, E.,
Murray, J.,
Nurock, S.,
Orrell, M.,
O'Brien, J.,
Poppe, M.,
Thomas, A.,
Walwyn, R.,
Wilson, K.,
Burns, A.
Objective: Depression is common in dementia, causing considerable distress and other negative impacts. Treating it is a clinical priority, but the evidence base is sparse and equivocal. This trial aimed to determine clinical effectiveness of sertraline and mirtazapine in reducing depression 13 weeks post randomisation compared with placebo.; Design: Multicentre, parallel-group, double-blind placebo-controlled randomised controlled […]
Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures
Galasko, Douglas R,
Peskind, Elaine,
Clark, Christopher M.,
Quinn, Joseph F.,
Ringman, John M.,
Jicha, Gregory A.,
Cotman, Carl,
Cottrell, Barbara,
Montine, Thomas J.,
Thomas, Ronald G.,
Aisen, Paul
Objective: To evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid (CSF) biomarkers.; Design: Double-blind, placebo-controlled clinical trial.; Setting: Academic medical centers.; Participants: Subjects with mild to moderate Alzheimer disease.; Intervention: Random assignment to treatment for 16 weeks with 800 IU/d of vitamin E (α-tocopherol) plus 500 mg/d of vitamin C […]
Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD
Egan, Michael,
Yaari, Roy,
Liu, Lian,
Ryan, Michael,
Peng, Yahong,
Lines, Christopher,
Michelson, David
We performed a clinical trial to evaluate the effects of the histamine subtype-3 receptor inverse agonist MK- 0249 on cognition in AD patients. Mild-to-moderate AD patients were randomized 1:1 to 4 weeks of double-blind daily treatment with oral MK-0249 5-mg or placebo. Pharmacokinetic and PET data suggested that MK-0249 5-mg daily would achieve approximately 85% […]
Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study
Dubois, Bruno,
Tolosa, Eduardo,
Katzenschlager, Regina,
Emre, Murat,
Lees, Andrew J.,
Schumann, Günther,
Pourcher, Emmanuelle,
Gray, Julian,
Thomas, Gail,
Swartz, Jina,
Hsu, Timothy,
Moline, Margaret L.
Parkinson’s disease dementia (PDD) is associated with cholinergic deficits. This report presents an efficacy and safety study of the acetylcholinesterase inhibitor donepezil hydrochloride in PDD. PDD patients (n = 550) were randomized to donepezil (5 or 10 mg) or placebo for 24 weeks. Coprimary end points were the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and […]